RxDoctor Payments Data

Wendy Johnson, MD

Cardiovascular Disease · South Weymouth, MANPI 1942224654

Payments from drug & device makers

$497in general payments, 2019–2025

Across 6 payments — averaging $82.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$212
  • Amgen$128
  • E.r. Squibb & Sons, L.L.C.$118
  • Medtronic$15
  • Novartis$13
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11

What the payments were for

  • Food & beverage$28557%
  • Education$21243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$497 in reported general payments places this provider in the 35th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$396,336
Medicare patients
2,112
Services billed
5,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban513$669,387
EntrestoSacubitril/Valsartan196$317,377
JardianceEmpagliflozin135$191,655
XareltoRivaroxaban70$84,432
Repatha SureclickEvolocumab27$24,400
Metoprolol Succinate827$19,669
Atorvastatin Calcium651$11,025
Ezetimibe123$6,990
Doxazosin Mesylate217$6,981
Rosuvastatin Calcium182$6,726
Digoxin40$6,717
Losartan Potassium473$5,961
Torsemide156$4,280
Amlodipine Besylate339$3,047
Lisinopril280$2,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$317,377196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in South Weymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →